The Institute of Nuclear Medicine provides the complete spectrum of radioisotope-based metabolic imaging including imaging of the CNS and targeted therapies, with approximately 3600 PET scans, 2000 SPECT scans and 400 therapeutic applications per year.
The institute hosts the multidisciplinary research group ‘Clinical Radiopharmacy’ (Prof. Martin A. Walter) that is dedicated to combining radiolabeling of biologically relevant molecules with high-throughput techniques such as microfluidics to deepen the understanding of tumor biology and bring precision medicine platforms into clinical practice.
The ‘Clinical Radiopharmacy’ research group comprises the infrastructure to synthesize and radiolabel new molecules, translate them into patients, and evaluate their benefits and harms in prospective trials. Its preclinical branch comprising chemists, biologists, biochemists and physicians focuses on developing and clinically translating novel radiotheranostics for tumor detection and treatment, including long-term cell tracking via PET and tumor-targeted nanoparticles for controlled drug delivery. The clinical branch of the ‘Clinical Radiopharmacy’ research group is composed of physicians, epidemiologists and statisticians, who focus on assessing benefits and harms of diagnostic and therapeutic tracers in prospective trials and meta-analyses. For these projects, the research group collaborates with scientists of various fields in Europe, Australia and the US.
- Development and clinical translation of novel diagnostic and therapeutic radiotracers
- Radioisotope-based cell tracking
- Radioisotope-based nanomedicine
|Prof. Dr. med. Thomas Krause|